In the last trading session, 1.47 million shares of the Travere Therapeutics Inc (NASDAQ:TVTX) were traded, and its beta was 0.97. Most recently the company’s share price was $14.83, and it changed around $0.33 or 2.28% from the last close, which brings the market valuation of the company to $1.32B. TVTX currently trades at a discount to its 52-week high of $25.29, offering almost -70.53% off that amount. The share price’s 52-week low was $5.12, which indicates that the current value has risen by an impressive 65.48% since then. We note from Travere Therapeutics Inc’s average daily trading volume that its 10-day average is 2.26 million shares, with the 3-month average coming to 1.79 million.
Travere Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.13. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended TVTX as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight.
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Instantly TVTX has showed a green trend with a performance of 2.28% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 15.96 on recent trading dayincreased the stock’s daily price by 7.08%. The company’s shares are currently down -14.87% year-to-date, but still down -2.24% over the last five days. On the other hand, Travere Therapeutics Inc (NASDAQ:TVTX) is -24.84% down in the 30-day period. We can see from the shorts that 11.56 million shares have been sold at a short interest cover period of 7.05 day(s).
The consensus price target as assigned by Wall Street analysts is $30, which translates to bulls needing to increase their stock price by 50.57% from its current value. Analyst projections state that TVTX is forecast to be at a low of $27 and a high of $33.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -3.34%.
TVTX Dividends
Travere Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-19.
Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.70% of Travere Therapeutics Inc shares, and 109.27% of them are in the hands of institutional investors. The stock currently has a share float of 110.04%. Travere Therapeutics Inc stock is held by 276.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 9.8642% of the shares, which is about 7.64 million shares worth $62.84 million.
ARMISTICE CAPITAL, LLC, with 9.6774% or 7.5 million shares worth $61.65 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Delaware Group Equity Funds V-Macquarie Small Cap Core Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024 . The former held 3.45 shares worth $51.19 million, making up 3.89% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 2.71 shares worth around $40.21 million, which represents about 3.05% of the total shares outstanding.
